KPV Research Overview
An overview of KPV, a tripeptide with anti-inflammatory properties studied in intestinal and dermatological research.
Scientific background / literature overview only. Discussion of published research does not describe the intended use of Novex Peptide products.
Introduction
> **Research Context Notice** — This article summarises published scientific literature for educational and research-reference purposes only. Discussion of experimental, preclinical or clinical findings does not represent a permitted use of Novex Peptide products. Products supplied by Novex Peptide are intended exclusively for in-vitro laboratory research and are not intended for human or animal administration.
KPV is a tripeptide consisting of lysine, proline, and valine. It is the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH) and has been studied for its anti-inflammatory properties in animal and in vitro models.
Mechanism of Action
Anti-Inflammatory Pathway
KPV appears to exert anti-inflammatory effects through multiple pathways. Research suggests it may inhibit the activation of NF-κB, a key transcription factor in inflammatory signalling.
Melanocortin Pathway
As a fragment of α-MSH, KPV may interact with melanocortin receptors, though its activity at these receptors is reduced compared to the full-length peptide.
Intestinal Barrier Function
Research in animal models of inflammatory bowel disease has investigated KPV's effects on intestinal epithelial barrier integrity and inflammatory cytokine production.
Current Research
Intestinal Research
Animal studies using models of colitis have investigated KPV's effects on intestinal inflammation, mucosal healing, and cytokine profiles.
Dermal Research
In vitro studies have explored KPV's effects on skin inflammation, wound healing, and keratinocyte function.
Systemic Inflammation
Some research has investigated KPV's effects on systemic inflammatory markers in animal models.
Chemical Properties
Reference values describe the named molecular form in [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/125672). Salt, counterion, hydration and formulation may change the mass of supplied material. Confirm the supplied form before quantitative use.
Storage Considerations
Follow the supported product label and compound-specific laboratory protocol. Solution stability depends on the exact material, solvent, concentration and storage conditions; there is no universal refrigerated shelf life or freezing protocol. Obtain missing stability information before preparation. Where validated, use aliquots to minimise repeated freeze-thaw cycles.
Testing Methods
KPV batches should be verified by:
Research Limitations
KPV is supplied for in-vitro laboratory research only. Published preclinical literature includes in-vivo animal studies. References to such studies are provided solely as scientific background and do not indicate that Novex Peptide products are supplied for animal administration. No clinical trials have confirmed efficacy in humans. No medical, therapeutic, or dosing claims are made. KPV is not approved for human therapeutic use by any regulatory authority.
References
- 1.Brzoska T, et al. KPV and Anti-Inflammatory Effects. Ann N Y Acad Sci. 2008;1124:97-106.
- 2.Luger TA, et al. α-MSH and Inflammation. Horm Metab Res. 2007;39(4):267-273.
- 3.Muc W, et al. KPV and Intestinal Inflammation. J Physiol Pharmacol. 2018;69(2):219-227.
Research use only. This article is for educational purposes only and does not constitute advice for any application involving human use. No medical claims are made.
